retatrutide research study FDA Approval Status 2026: Everything We Know So Far Retatrutide for Weight Loss: TRIUMPH-1

The substantial weight loss achieved with GLP-1 receptor agonists and dual GIP/GLP-1 agonistsapproximately 15% with semaglutide 2.4 mg (Wegovy) and up to 21% with higher doses of tirzepatide (Zepbound) in clinical trialsoccurs primarily through appetite suppression and reduced caloric intake rather than increased metabolic rate

BMC Complement Altern Med

Together, they will examine what it takes to sustain progress and define success beyond short-term weight loss, offering a grounded perspective on long-term health and the evolving needs of patients

Frequently Asked Questions What foods should I avoid when taking retatrutide

The question of weight regain following retatrutide discontinuation is not yet answered in published data

Wallner, M